Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?

Michael J Birrer; Ilaria Betella; Lainie P Martin; Kathleen N Moore

doi:10.1634/theoncologist.2018-0459

Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?

Oncologist. 2019 Apr;24(4):425-429. doi: 10.1634/theoncologist.2018-0459. Epub 2019 Jan 11.

Authors

Michael J Birrer¹, Ilaria Betella², Lainie P Martin³, Kathleen N Moore⁴

Affiliations

¹ O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA mbirrer@uab.edu.
² O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA.
³ Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
⁴ Stephenson Oklahoma Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.

Abstract

Prognosis for women with epithelial ovarian cancer remains poor. One new molecular target in epithelial ovarian cancer is folate receptor alpha (FRα). This commentary discusses the characteristics that contribute to its attractiveness as a candidate for therapeutic intervention.

MeSH terms

Antineoplastic Agents / therapeutic use*
Carcinoma, Ovarian Epithelial / drug therapy*
Carcinoma, Ovarian Epithelial / metabolism
Carcinoma, Ovarian Epithelial / pathology
Clinical Trials as Topic
Female
Folate Receptor 1 / antagonists & inhibitors*
Humans
Molecular Targeted Therapy
Prognosis

Substances

Antineoplastic Agents
Folate Receptor 1